Immune Checkpoint Inhibitor Therapy Induced Plexopathy (P10-2.006)

Immune checkpoint inhibitors (ICI) are associated with a variety of immune-related adverse events (irAEs). IrAEs are under diagnosed as they present with a spectrum of non-specific, and often initially subtle, symptoms. These symptoms typically develop shortly after initiation of ICI. Patients may present with symptoms suggestive of disorders such as myasthenia gravis, encephalitis/meningitis, inflammatory polyradiculopathies, or peripheral neuropathy. In this report, we present the case of a patient, with newly diagnosed malignant melanoma, who began to experience a variety of symptoms including bilateral lower extremity weakness weeks after initiating neoadjuvant Ipilimumab & Nivolumab (Ipi/Nivo).